In todays episode we learn about one of our central and service projects, which serves all research projects with their service on experimental and computational single-cell analysis with high spatial resolution.

A Podcast of our IRTG together with PIs Ulrike Protzer, Sabrina Schreiner and Marco Binder. Enjoy listening!

In this episode we interview our guests, the two TRR graduates Oliver Grünvogel and Julija Miller together with Peter Wimmer as a successful pharmaceutical manager to get insights about career as researcher in industry.

Key factor for successful therapeutic vaccination against chronic hepatitis B identified: Our colleagues in Munich found that the success of therapeutic hepatitis B vaccination depends on efficient priming of HBV-specific CD4 T cells. The results have been published in the Journal of Hepatology.

In today's episode, our PhD- and MD-students present the integrated graduate school of the TRR. A very varied and informative compilation. Enjoy listening!

The 5th Podcast is a very special edition which gives an impression and snapshots of the international conference, which took place from 29-31.5.2022 in Freiburg. Listen to wraps ups of the highlights of some of our invited speakers ...and feel the spirit of the international research community in the field of viral hepatitis and beyond.

Heute ist Tobias im Gespräch mit einem unserer Projektleiter, Percy Knolle, und seinem PostDoc Michael Dudek. Sie unterhalten sich über die neusten Erkenntnisse zu auto-aggressiven T-Zellen und Autoimmunität in NASH. Das hat auch Implikation für die gesamte Bandbreite der Virushepatitis.

Shownotes:

Dudek, M., Pfister, D., Donakonda, S. et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature 592, 444–449 (2021)“

TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection | Science | Publications

Mehr zu unserer Forschung erfahrt Ihr auch auf der Konfernz in Freiburg am 30./31.5.2022: TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection | News | SAVE THE DATE 30/31.5.2022.

Wir freuen uns auf Euren Besuch, die Teilnahme ist kostenfrei!

Heute ist Tobias im Gespräch mit Stephan Urban, Teilprojektleiter des TRR179, der im Rahmen seiner Forschung das Medikament zur Behandlung von Hepatitis D entdeckt hat.

Shownotes:

Erstes Medikament gegen Hepatitis D von der Europäischen Kommission zugelassen (uni-heidelberg.de)

TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection

Universitätsklinikum Heidelberg: Molecular Virology (uni-heidelberg.de)

Urban S, Neumann-Haefelin C, Lampertico P Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease Gut 2021;70:1782-1794.